As the Biden administration and the new Congress examine policies to reduce prescription drug costs, one place to start is officially revoking the so-called rebate rule, which was hastily — and likely illegally — finalized in the remaining days of
Moving reimbursement for those drugs into Part D could have a “massive impact overnight”
Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion.
Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion In case you missed it, a new report from The Coalition for Affordable Prescription Drugs (CAPD) and conducted by Matrix Global
The Pharmaceutical Care Management Association, which represents the pharmacy middlemen that help decide how a drug will be covered by insurance, said in an email that its members are “stepping up to support the government’s efforts” to provide effective Covid-19 treatments and that they are “making voluntary payments to pharmacies in order to maintain appropriate access to the medications for patients.”
The Pharmaceutical Research and Manufacturers of America, which strongly opposes the provisions, hit back on Monday, saying that Build Back Better fails to address the role of “middlemen” known as pharmacy benefit managers, saying the package should do more to ensure that savings actually make their way to patients at the pharmacy counter.
PBMs and Pharmacies Pharmacy Benefit Companies Support Rural Independent Pharmacies Pharmacies are important points of care for many patients across the U.S. This can especially be true for patients in rural areas, who may depend on their pharmacist for clinical
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. For Prescriptions It’s Home Sweet Home for Patients…
©2024 PCMA. All Rights Reserved.
